Axcynsis, Next Generation of ADC

Singapore, December 26, 2023 – Axcynsis Therapeutics today announced that it is presenting at Biotech Showcase™ 2024. This year, registered attendees can view Axcynsis Therapeutics’ presentation live and access a recorded version beginning November 27th – SIX weeks before the event.  With 24×7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Dr. Bin Zou will be presenting Axcynsis Therapeutics at the Biotech Showcase.

January 8th, 2024, at 2:45 pm Pacific time

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. It proudly announced its participation in the Biotech Showcase on January 8th, 2024, in San Francisco.

“We are honored to be presenting at the Biotech Showcase. Axcynsis Therapeutics is dedicated to developing the next generation of ADC platforms and drug candidates, and Axcynsis is uniquely positioned to tackle the substantial and urgent unmet needs in cancer therapeutics.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Axcynsis Therapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”


Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.


Axcynsis Therapeutics stands at the forefront of innovation in antibody-drug conjugates (ADCs). Fueled by a robust intellectual property portfolio, Our pioneering approach seamlessly integrates advanced antibody discovery, a proprietary payload, and a novel mechanism of action, positioning us as a key player in overcoming drug resistance encountered with current ADC payloads like DM1, MMAE, and DXd.

Through strategic deployment of site-specific conjugation technologies, our ADC products consistently demonstrate superior efficacy and an expanded therapeutic window, validated by compelling results in diverse in vivo models and pre-tox studies.

In a remarkable year since our inception, Axcynsis Therapeutics has successfully developed three highly differentiated assets, each targeting distinct tumor antigens. These assets, recognized as potential best-in-class candidates, underscore our unwavering commitment to delivering transformative solutions in cancer treatment.

Recognizing the magnitude of these unmet needs, Axcynsis Therapeutics is actively seeking strategic partnerships and investments to expedite the development of our lead assets. With a clear path to achieve IND by Q3 and Phase I trials by Q4 of 2024, we invite collaborators to join us in addressing the critical gaps in cancer therapeutics and substantially impacting patient outcomes.


Bin Zou

Follow Axcynsis Therapeutics Biotech Showcase at @EBDGroup and @Demy_Colton and #Axcynsis Therapeutics with #BiotechShowcase.